Cediranib

Price	$2
Package	1kg

Product Details

Product Name: Cediranib	CAS No.: 288383-20-0
Min. Order: 1kg	Purity: 99%
Supply Ability: 100kg	Release date: 2019/07/06
Product Number:: WM.819

Cediranib Basic information

Anticancer drugs

Product Name:	Cediranib
Synonyms:	Cediranib;4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;Cadiranib (AZD2171);Cediranib(AZD2171);AZD2171;Recentin;Cadiranib;Cediranib R
CAS:	288383-20-0
MF:	C25H27FN4O3
MW:	450.51
EINECS:	1308068-626-2
Product Categories:	APIs;Antineoplastic;Inhibitors
Mol File:	288383-20-0.mol

Cediranib Chemical Properties

density

1.285

Safety Information

MSDS Information

Cediranib Usage And Synthesis

Anticancer drugs

Cediranib is an oral anticancer drug , it is successfully developed by the US AstraZeneca company , its trade name is recentin, this product is an efficient VEGFR tyrosine kinase inhibitor, it is capable of inhibiting all known VEGFR tyrosine kinases ( including VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR). Cediranib can inhibit VEGF-induced angiogenesis, neovascularization survival and human tumor xenograft cell growth.Clinical trail phase I for non-small cell lung cancer (abbreviated NSCLC) patients shows that cediranib in combination with PC programs has a significant antitumor effect . Clinical trail phaseⅡ/Ⅲ BR24 focuses on using cediranib 30mg as a first-line treatment of NSCLC ,which demonstrates that it has anti-tumor effect, but it has a higher incidence of adverse events, including diarrhea, dehydration, hand-foot syndrome, hypertension and neutropenia disease. Therefore, there is the decision to stop clinical trials. Repeated assessments about toxicity and dose of the combination of drugs suggest that part of the adverse effects are dose-related , dose reduction may be tried to improve drug tolerance. In view of this conclusion, in 2009, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) launched a cediranib clinical trail phase Ⅲ (BR29) for progressive NSCLC patients , the dose was adjusted to 20mg. The results have not been reported.
In 2009 ,European Society for Medical Oncology (ESMO) Annual report which is about cediranib treatment of metastatic renal cell carcinoma (referred mRCC) clinical trail phase II shows that cediranib treatment group tumor volume reducing rate is higher than the placebo group. Zurita tested Cediranib pretreatment serum cytokines and angiogenic factors ,and found that patients having low IL-10, VEGF, PIGF, SCF and MIG concentration during baseline time , have the more obvious tumor volume reduction after treatment.
The above information is edited by the chemicalbook of Tian Ye.

Uses

Cediranib (AZD2171) inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively.

Company Profile Introduction

Established in 2014,Career Henan Chemical Co. is a manufacturerspecializing in the sale of fine chemicals. Mainly deals in the sales of: Pharmaceutical intermediates OLED intermediates： Pharmaceutical intermediates; OLED intermediates;

Recommended supplier

Product name	Price		Suppliers	Update time
Cediranib	$35.00/2mg	VIP5Y	TargetMol Chemicals Inc.	2024-11-19
Cediranib	$10.00/1KG	VIP6Y	Hebei Weibang Biotechnology Co., Ltd	2024-11-05
Cediranib	$0.00/25KG	VIP5Y	Hebei Mojin Biotechnology Co., Ltd	2023-09-06
Cediranib	$12.00/1KG		Hong Kong Tiansheng New Material Trading Co., Ltd	2022-01-10
Cediranib	$1.00/1g		Wuhan Boyuan Import & Export Co., LTD	2021-08-12
Cediranib USP/EP/BP	$1.10/1g	VIP4Y	Dideu Industries Group Limited	2021-07-01
Cediranib	$0.00/1Kg	VIP6Y	Shaanxi Dideu Medichem Co. Ltd	2020-04-30
Cediranib	$5.99/1KG		Hong Kong Tiansheng New Material Trading Co., Ltd	2021-12-24

Product Details

Company Profile Introduction

You may like

Recommended supplier

career henan chemical co